TBXT and cancer: The decrease in the MDA content was found to be 21.87% and 43.01% with the treatment from PFT-HSA-TFT-Cy7 at 1 μM and 3 μM, respectively, while 11.73% and 35.75% from PFT-Hcy-HSA-Cy7 at similar concentrations in the cancer animal model.